Metabolic and behavioral effects of chronic olanzapine treatment and cafeteria diet in rats

Behavioural Pharmacology

Volumn 21, Issue 7, 2010, Pages 668-675

  Muller, Alexandre P ^a   Tort, Ana H ^a   Gnoatto, Jussânia ^a   Moreira, Julia D ^a   Vinadé, Elsa R ^a   Perry, Marcos L ^a   Souza, Diogo O ^a   Lara, Diogo R ^b   Portela, Luis V ^a  

^a Instituto de Ciencias Biologicas e da Saude Pontifical Catholic University of Minas Gerais   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Highly palatable diet; Insulin resistance; Intra abdominal obesity; Locomotor activity; Memory; Olanzapine; Rat

Indexed keywords

OLANZAPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; AVOIDANCE BEHAVIOR; BODY WEIGHT; BRAIN FUNCTION; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; EPIDIDYMIS FAT; FAST FOOD; GLUCOSE INTOLERANCE; LOCOMOTION; MALE; MAZE TEST; MEMORY CONSOLIDATION; MESENTERY; METABOLISM; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; RAT; TRANQUILIZING ACTIVITY;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BENZODIAZEPINES; DIET; DIETARY FATS; EATING; FAST FOODS; GLUCOSE INTOLERANCE; HUMANS; MALE; MAZE LEARNING; MOTOR ACTIVITY; OBESITY; RATS; RATS, WISTAR;

EID: 77957312623     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32833e7f2a     Document Type: Article

References (43)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC,Weiden PJ (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696.
2. Brown S, Birtwistle J, Roe L, Thompson C (1999). The unhealthy lifestyle of people with schizophrenia. Psychol Med 29:697-701.
3. Casey DE (2005). Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 118 (Suppl 2):15S-22S.
4. Casey DE, Zorn SH (2001). The pharmacology of weight gain with antipsychotics. J Clin Psychiatry 62 (Suppl 7):4-10.
5. Chaves VE, Frasson D, Martins-Santos ME, Boschini RP, Garofalo MA, Festuccia WT, et al. (2006). Glyceroneogenesis is reduced and glucose uptake is increased in adipose tissue from cafeteria diet-fed rats independently of tissue sympathetic innervation. J Nutr 136:2475-2480.
6. Chintoh AF, Mann SW, Lam TK, Giacca A, Remington G (2008). Insulin resistance following continuous, chronic olanzapine treatment: an animal model. Schizophr Res 104:23-30.
7. Cooper GD, Pickavance LC, Wilding JP, Halford JC, Goudie AJ (2005). A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) 181:80-89.
8. Cooper GD, Pickavance LC, Wilding JP, Harrold JA, Halford JC, Goudie AJ (2007). Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol 21:405-413.
9. Cooper GD, Harrold JA, Halford JC, Goudie AJ (2008). Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 32:428-436.
10. Dall'Igna OP, Tort AB, Souza DO, Lara DR (2005). Cinnarizine has an atypical antipsychotic profile in animal models of psychosis. J Psychopharmacol 19:342-346.
11. Didriksen M, Kreilgaard M, Arnt J (2006). Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. Eur J Pharmacol 542:108-115.
12. Dietrich MO, Muller A, Bolos M, Carro E, Perry ML, Portela LV, et al. (2007). Western style diet impairs entrance of blood-borne insulin-like growth factor-1 into the brain. Neuromolecular Med 9:324-330.
13. Egashira N, Ishigami N, Mishima K, Iwasaki K, Oishi R, Fujiwara M (2008). Delta9-Tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats. Prog Neuropsychopharmacol Biol Psychiatry 32:499-506.
14. Frye CA, Seliga AM (2003). Olanzapine's effects to reduce fear and anxiety and enhance social interactions coincide with increased progestin concentrations of ovariectomized rats. Psychoneuroendocrinology 28:657-673.
15. Goudie AJ, Cole JC (2008). Switching antipsychotics. Antipsychotic tolerance, withdrawal and relapse: unresolved issues and research implications. J Psychopharmacol 22:815-817.
16. Goudie AJ, Cole JC, Sumnall HR (2007). Olanzapine and JL13 induce cross-tolerance to the clozapine discriminative stimulus in rats. Behav Pharmacol 18:9-17.
17. Green MF, Kern RS, Braff DL, Mintz J (2000). Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the 'right stuff'? Schizophr Bull 26:119-136.
18. Haupt DW (2006). Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 16 (Suppl 3):S149-S155.
19. Kirk SL, Glazebrook J, Grayson B, Neill JC, Reynolds GP (2009). Olanzapineinduced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology (Berl) 207:119-125.
20. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223.
21. Locchi F, Dall'olio R, Gandolfi O, Rimondini R (2008). Olanzapine counteracts stress-induced anxiety-like behavior in rats. Neurosci Lett 438:146-149.
22. McCreadie RG (2003). Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 183:534-539.
23. Mead A, Li M, Kapur S (2008). Clozapine and olanzapine exhibit an intrinsic anxiolytic property in two conditioned fear paradigms: contrast with haloperidol and chlordiazepoxide. Pharmacol Biochem Behav 90:551-562.
24. Minet-Ringuet J, Even PC, Guesdon B, Tome D, de Beaurepaire R (2005). Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection. Behav Brain Res 163:204-211.
25. Minet-Ringuet J, Even PC, Lacroix M, Tome D, de Beaurepaire R (2006). A model for antipsychotic-induced obesity in the male rat. Psychopharmacology (Berl) 187:447-454.
26. Molteni R, Barnard RJ, Ying Z, Roberts CK, Gomez-Pinilla F (2002). A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. Neuroscience 112:803-814.
27. Molteni R, Wu A, Vaynman S, Ying Z, Barnard RJ, Gomez-Pinilla F (2004). Exercise reverses the harmful effects of consumption of a high-fat diet on synaptic and behavioral plasticity associated to the action of brain-derived neurotrophic factor. Neuroscience 123:429-440.
28. Muller AP, Cammarota M, de Oliveira Dietrich M, Rotta LN, Portela LV, Souza DO, et al. (2008). Different effect of high fat diet and physical exercise in the hippocampal signaling. Neurochem Res 33:880-885.
29. Newcomer JW (2004). Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 65 (Suppl 18):36-46.
30. Newcomer JW (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 (Suppl 1):1-93.
31. Newcomer JW (2007). Metabolic syndrome and mental illness. Am J Manag Care 13:S170-S177.
32. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G (2002). Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59:337-345.
33. Parekh PI, Petro AE, Tiller JM, Feinglos MN, Surwit RS (1998). Reversal of dietinduced obesity and diabetes in C57BL/6J mice. Metabolism 47:1089-1096.
34. Rauggi R, Scheggi S, Cassanelli A, De Montis MG, Tagliamonte A, Gambarana C (2005). The mesolimbic dopaminergic response to novel palatable food consum ption increases dopamine-D1 receptor-mediated signalling with complex modifications of the DARPP-32 phosphorylation pattern. J Neurochem 92:867-877.
35. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S (2007). 'Breakthrough' dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 27:2979-2986.
36. Souza CG, Moreira JD, Siqueira IR, Pereira AG, Rieger DK, Souza DO, et al. (2007). Highly palatable diet consumption increases protein oxidation in rat frontal cortex and anxiety-like behavior. Life Sci 81:198-203.
37. Stuchlik A, Rehakova L, Telensky P, Vales K (2007). Morris water maze learning in Long-Evans rats is differentially affected by blockade of D1-like and D2-like dopamine receptors. Neurosci Lett 422:169-174.
38. Terry AV Jr, Hill WD, Parikh V, Evans DR, Waller JL, Mahadik SP (2002). Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats. Psychopharmacology (Berl) 164:360-368.
39. Terry AV Jr,Warner SE, Vandenhuerk L, Pillai A, Mahadik SP, Zhang G, Bartlett MG (2008). Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats. Neuroscience 156:1005-1016.
40. Tort AB, Neto WP, Amaral OB, Kazlauckas V, Souza DO, Lara DR (2006). A simple webcam-based approach for the measurement of rodent locomotion and other behavioural parameters. J Neurosci Methods 157: 91-97.
41. Tracy RP (2001). Is visceral adiposity the 'enemy within'? Arterioscler Thromb Vasc Biol 21:881-883.
42. Waitzkin L (1966). A survey for unknown diabetics in a mental hospital. II. Men from age fifty. Diabetes 15:164-172.
43. Zhang W, Bymaster FP (1999). The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology (Berl) 141:267-278